Medifocus, Inc. Announces FDA PMA Supplement Approval for New Labeling Based on Successful Completion of FDA Post Approval Study (PAS) for the Prolieve® Thermodilatation(TM) Device

Stock Information for Medifocus Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Medifocus Inc.

Medifocus, Inc. Announces SEC Deregistration
IIROC Trading Halt - MFS
Medifocus Inc. Announces Resignation of Chief Financial Officer
Medifocus Inc. Announces Delayed Filing of Annual Disclosure Documents Pursuant to OSC Instrument 51-502
Medifocus, Inc. Announces Increase in Revenue and Positive Cash Flow from Operation in Fiscal Year Ended March 31, 2019 and Global Market Expansion with Prolieve(R) Procedures Performed in Singapore
Medifocus, Inc. Announces Global Market Expansion with Prolieve® Performed and Reimbursed by Insurance Carriers in Hong Kong
Medifocus, Inc. Announces Recent Publication Highlighting Its Focal Therapy for Prostate and Breast Cancer Treatment Initiatives
Uptick Newswire's Stock Day Podcast Hosts Medifocus, Inc.'s CEO to Discuss Their Minimally Invasive Breakthrough Treatments for Prostate and Breast Cancers

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.